Rhizen Pharmaceutica
Rhizen Pharmaceuticals S.A. announces initiation of Phase 2 study of RV1001 in dogs with T- or B-cell Lymphoma
September 22, 2015 07:00 ET | Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Sept. 22, 2015 (GLOBE NEWSWIRE) -- ´╗┐Rhizen Pharmaceuticals S.A. has announced the initiation of Phase 2 study of RV1001, a novel, oral selective inhibitor of PI3K...
Rhizen Pharmaceutica
Rhizen Pharmaceuticals Announces Out-licensing Agreement for TGR-1202, a Novel Next Generation PI3K-delta Inhibitor
September 23, 2014 09:00 ET | Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Sept. 23, 2014 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. today announced an out-licensing agreement for TGR-1202, a novel next generation PI3K-delta inhibitor. TG...
Rhizen Logo
Rhizen Pharmaceuticals S.A Announces a Scientific Presentation on the PI3K-Delta Inhibitor, TGR-1202, at the XV International Workshop on Chronic Lymphocytic Leukemia at Cologne, Germany
September 09, 2013 09:04 ET | Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Sept. 9, 2013 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals announces a scientific poster presentation on the PI3K-delta inhibitor, TGR-1202, by the Duke University...